

Kazia Therapeutics Ltd

00:56 08 May 2019

Kazia Therapeutics gains new substantial holder in The Bank of New York Mellon

Kazia Therapeutics Limited (ASX:KZA) has a new substantial holder in The Bank of New York Mellon Corporation (NYSE:BK) which recently staked a 27.09% interest.

The world's largest custodian bank now holds a total of 16,840,686 securities in the Australian oncology-focused biotech company.

Kazia Therapeutics chief executive officer James Garner said the superior results from the ongoing study of GDC-0084 in newly-diagnosed glioblastoma patients was an important milestone for the company.

He added the current, second stage of the two-part study (which began in September) will transition into observing more patients, with higher doses of the drug.

READ: Kazia Therapeutics' ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients

Garner continued: "One of the exciting things about our drug GDC-0084 is that its designed to cross the blood-brain barrier.

"We are focusing on newly-diagnosed patients in earlier stages of the disease and we think we can offer a much bigger benefit there."

The company confirmed a higher maximum tolerated dose (MTD) of 60 milligrams in new safety data from its ongoing phase-IIa clinical study earlier this week.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

Price: 0.57

Market Cap: \$35.44 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: KZA

Listing: ASX

52 week High Low
0.8 0.32

Sector: Pharma & Biotech

Website: www.kaziatherapeutics.com

Company Synopsis:

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) pipeline includes two clinical-stage drug development candidates.

action@proactiveinvestors.com

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).